Description
A monoclonal antibody against CD44 was shown to be a cancerous disease modifying antibody (CDMAB), preventing tumour growth and reducing tumour burden in cancer models including prostate and breast cancer by cytotoxicity.
Target
CD44
Target Alias Names
CD44 Molecule (Indian Blood Group), Hematopoietic Cell E- And L-Selectin Ligand, GP90 Lymphocyte Homing/Adhesion Receptor, Chondroitin Sulfate Proteoglycan 8, Extracellular Matrix Receptor III, Heparan Sulfate Proteoglycan, Phagocytic Glycoprotein 1, Hyaluronate Receptor, Hermes Antigen, ECMR-III, HUTCH-I, Epican, CDW44, MDU2, MDU3, MIC4, LHR, CD44 Antigen (Homing Function And Indian Blood Group System), Homing Function And Indian Blood Group System, Cell Surface Glycoprotein CD44, Phagocytic Glycoprotein I, Soluble CD44, CD44 Antigen, CSPG8, HCELL, PGP-1, PGP-I, MC56, Pgp1, IN
Isotype/Mimetic
Chimeric (mouse/human) IgG1
Animal-Derived Biomaterials Used
None
Sequence Available
No
Original Discovery Method
Human-derived phage display
Original Discovery Information Provided On Datasheet
No
Antibody/Binder Origins
Animal-free discovery, In vitro recombinant expression